Collaboration Seeks to Develop Prostate Cancer Companion Diagnostic for Local Lab Testing
Collaboration Seeks to Develop Prostate Cancer Companion Diagnostic for Local Lab Testing Clinical Lab Products
Онкология
Рак простаты
200 материалов по теме, собраны автоматически из проверенных источников
Онкология
Perioperative Apalutamide Improves Outcomes in High-Risk Localized Prostate Cancer
Perioperative Apalutamide Improves Outcomes in High-Risk Localized Prostate Cancer Pharmacy Practice News
Онкология
Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors | DelveInsight
Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors | DelveInsight PR Newswire
Онкология
Managing Side Effects of Treatment for Advanced Prostate Cancer
Managing Side Effects of Treatment for Advanced Prostate Cancer MedPage Today
Онкология
TRACE-I: Long-Term Outcomes of PSMA-Guided Salvage Surgery in Recurrent Prostate Cancer
TRACE-I: Long-Term Outcomes of PSMA-Guided Salvage Surgery in Recurrent Prostate Cancer Oncodaily
Онкология
В Госсовете Татарстана предложили сделать обязательной проверку мужчин на рак простаты
В Госсовете Татарстана предложили сделать обязательной проверку мужчин на рак простаты KazanFirst
Онкология
В Госсовете Татарстана предложили сделать обязательной проверку мужчин на рак простаты
В Госсовете Татарстана предложили сделать обязательной проверку мужчин на рак простаты KazanFirst
Онкология
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial Nature
Онкология
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months Cure Today
Онкология
Targeted radioactive therapy may help delay spread of recurrent prostate cancer
Adding the targeted radioactive drug 177Lu-PNT2002 to stereotactic body radiation therapy, or SBRT, may help keep recurrent prostate cancer under control longer than SBRT alone, according to new research led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Онкология
Mercy Medical Center Expands Prostate Cancer Treatment Options With Advanced TrueBeam Technology | Newswise
Mercy Medical Center Expands Prostate Cancer Treatment Options With Advanced TrueBeam Technology | Newswise Newswise
Онкология
Targeted radioactive therapy may help delay spread of recurrent prostate cancer, UCLA study suggests | Newswise
Targeted radioactive therapy may help delay spread of recurrent prostate cancer, UCLA study suggests | Newswise Newswise
🎗️
Онкология
Beyond hormone therapy: what’s the next wave in prostate cancer?
Beyond hormone therapy: what’s the next wave in prostate cancer? Labiotech.eu
Онкология
More men living longer with incurable prostate cancer, report finds
Men in England diagnosed with incurable advanced prostate cancer are more likely to survive for at least three years than they were a decade ago, according to an analysis by the London School of Hygiene & Tropical Medicine (LSHTM) and partners.
🎗️
Онкология
Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer Business Wire